ArticleInvestigative and clinical urology2026
Impact of carcinoma
Article in Investigative and clinical urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCarcinoma MATERIALS AND
methodsA retrospective multicenter study was conducted using data from 2,553 patients who underwent TURB followed by RC between 2010 and 2019 across eleven Korean institutions. Kaplan-Meier survival curves and Cox proportional hazards models were used to assess the association of CIS at TURB and RC with RFS and CSS, adjusting for clinicopathological variables.
resultsCIS was identified in 731 TURB specimens (28.6%) and 821 RC specimens (32.2%). Patients with CIS at TURB had significantly higher RFS (p<0.001) and CSS (p=0.002) compared to those without. In multivariate analysis, CIS at TURB was independently associated with better RFS (hazard ratio [HR] 0.787, p=0.001) but not CSS (HR 0.989, p=0.905). CIS at RC showed no significant association with either RFS or CSS. Independent predictors of poor survival included advanced stage, lymph node involvement, lymphovascular invasion, and positive surgical margins. Adjuvant therapy was associated with improved CSS.
conclusionsCIS at TURB is associated with a lower recurrence risk following RC, whereas CIS in RC specimens has limited prognostic impact. These findings suggest CIS at TURB may carry different prognostic implications than traditionally assumed, warranting careful clinical interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.